EMA’s Clinical Trial Transparency Initiative Put on Hold — For Now

Clinical Trials Advisor
A A
The European Medicines Agency has postponed indefinitely a controversial transparency initiative that would make publicly available detailed information from clinical study reports contained in new drug applications.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00